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Abstract
Amidated neuropeptides play essential roles throughout the nervous and endocrine systems. Mice lacking peptidylglycine
a-amidating monooxygenase (PAM), the only enzyme capable of producing amidated peptides, are not viable. In the
amidation reaction, the reactant (glycine-extended peptide) is converted into a reaction intermediate (hydroxyglycine-
extended peptide) by the copper-dependent peptidylglycine-a-hydroxylating monooxygenase (PHM) domain of PAM. The
hydroxyglycine-extended peptide is then converted into amidated product by the peptidyl-a-hydroxyglycine a-amidating
lyase (PAL) domain of PAM. PHM and PAL are stitched together in vertebrates, but separated in some invertebrates such as
Drosophila and Hydra. In addition to its luminal catalytic domains, PAM includes a cytosolic domain that can enter the
nucleus following release from the membrane by c-secretase. In this work, several glycine- and hydroxyglycine-extended
peptides as well as amidated peptides were qualitatively and quantitatively assessed from pituitaries of wild-type mice and
mice with a single copy of the Pam gene (PAM
+/2) via liquid chromatography-mass spectrometry-based methods. We
provide the first evidence for the presence of a peptidyl-a-hydroxyglycine in vivo, indicating that the reaction intermediate
becomes free and is not handed directly from PHM to PAL in vertebrates. Wild-type mice fed a copper deficient diet and
PAM
+/2 mice exhibit similar behavioral deficits. While glycine-extended reaction intermediates accumulated in the PAM
+/2
mice and reflected dietary copper availability, amidated products were far more prevalent under the conditions examined,
suggesting that the behavioral deficits observed do not simply reflect a lack of amidated peptides.
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Introduction
Neuropeptide production typically involves endoproteolytic
cleavage of prohormones by prohormone convertases, followed
by exoproteolytic cleavage by carboxypeptidase E. As the
prohormone and its cleaved products traverse the secretory
pathway, additional post-translational modifications occur. One
common modification is C-terminal a-amidation, a reaction
catalyzed only by peptidylglycine a-amidating monooxygenase
(PAM) [1,2]. The C-terminal amide group often increases the
affinity of the peptide for its receptor, extends its half-life, and is
essential for biological activity [3]. Eliminating the PAM gene
prevents amidated peptide synthesis and is lethal in Drosophila [4]
and mouse [1]. PAM heterozygous (PAM
+/2) mice, with half the
PAM activity of wild-type (WT) mice, survive to adulthood and
reproduce [3]. However, PAM
+/2 mice are unable to maintain
body temperature in a cold room and show increased anxiety-like
behavior [5,6]. In vertebrates, PAM is a Type I integral
membrane protein; its luminal catalytic domains and unstructured
cytosolic domain are highly conserved. A c-secretase-mediated
cleavage within the PAM transmembrane domain generates a
cytosolic fragment that accumulates in the nucleus and is thought
to affect gene expression [5,7,8,9].
PAM has two enzymatic domains, peptidylglycine-a-hydroxyl-
ating monooxygenase (PHM) and peptidyl-a-hydroxyglycine a-
amidating lyase (PAL). PHM converts glycine-extended peptides
into hydroxyglycine-extended peptides by using molecular oxygen
to hydroxylate the a-carbon of the C-terminal glycine in a copper-
and ascorbate-dependent reaction. The hydroxyglycine-extended
peptide is then converted into the corresponding amidated peptide
and glyoxylate by PAL [10,11]. Although several glycine-extended
peptides (e.g., TRH-Gly [5,12,13] and gastrin-Gly [14,15]) have
been detected using radioimmunoassays, they have not been
studied systematically. Hydroxyglycine-extended peptides have
not been detected in vivo, suggesting that the product of the
monooxygenase reaction might be passed directly to the lyase. In
addition, PAM is amongst the small number of enzymes that
require copper for their catalytic function [16,17,18,19], and
behavioral deficits similar to those observed in PAM
+/2 mice were
observed in WT mice kept on a copper-deficient diet [5]. Whether
the deficits observed in PAM
+/2 and copper-deficient mice reflect
altered levels of amidation or changes in the regulatory processes
responsive to PAM and copper is not yet clear.
Liquid chromatography (LC)-mass spectrometry (MS) provides
both qualitative and quantitative information and enables sensitive
and accurate determination of neuropeptide forms [20,21,22,
PLoS ONE | www.plosone.org 1 December 2011 | Volume 6 | Issue 12 | e2867923,24]. Here we used two LC-MS based neuropeptidomics
approaches to evaluate the effects of PAM haploinsufficiency and
dietary copper deficiency on the levels of several glycine- and
hydroxyglycine-extended peptides as well as amidated peptides in
the mouse pituitary. We applied a standard isotope labeling
approach with LC-MS analysis to perform relative quantitation
for amidated peptides in PAM
+/2 mice maintained on a normal
diet compared to WT mice. We also found that endogenous
intermediateswere presentatmuchlowerlevelsthan theiramidated
counterparts, with the large dynamic range of peptide concentra-
tions making their identification and quantitation challenging. In
this case, following LC separation, we employed both matrix-
assisted laser desorption/ionization (MALDI) time-of-flight (TOF)
MS and electrospray ionization (ESI) ion-trap (IT) MS to identify
the intermediate peptides. After identification, the levels of glycine-
and hydroxyglycine-extended peptides were compared to those of
amidated products using MS-based peak intensities, and differences
were correlated to genetic and/or dietary manipulations. The
standard labeling approach requires multiple sample processing
steps and is well suited for assays of peptides at higher and similar
concentrations; however, these additional steps can cause peptides
already at low levels to be reduced to a point below the MS
detection limit [20,25]. Therefore, we used a label-free approach to
provide relative levels of the partially processed peptides [26,27].
We identified hydroxyglycine intermediates in pituitary lysates,
arguing against their transfer directly from PHM to PAL. Our
results demonstrate that glycine-extended peptides accumulate
when PAM levels are low and/or when copper availability is limited
but that amidated products still predominate.
Materials and Methods
Ethics Statement
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
Animal Protocols used for this study, numbers 2006-229 and
2009-517, both entitled Biochemistry and Physiology of Peptide
Amidation, conformed to the University of Connecticut Health
Center Animal Care Committee guidelines and the ARRIVE
guidelines have been followed.
Materials
HPLC grade solvents such as water and acetonitrile (ACN) with
0.1% formic acid (FA) and 0.01% trifluoroacetic acid (TFA) were
purchased fromFisherScientific(Pittsburgh,PA,USA).The MALDI
matrix, a-cyano-4-hydroxycinnamic acid (a-CHCA), was from
Sigma-Aldrich (St. Louis, MO, USA). Synthetic ACTH(1-13)-Gly
[ACTH(1-14)] (AnaSpec, Fremont, CA, USA) was converted into
ACTH(1-13)-Gly-OH using PHM catalytic core purified from stably
transfectedChinesehamsterovarycellmedium[3,4,28].The1.0 mL
reaction mixture contained 1.0 mMC u S O 4, 0.5 mM ascorbic acid,
100 mMp e p t i d e ,1 2mg PHMccQ170A, and 0.09 mg/mL bovine
liver catalase in 150 mM NaMES (Sigma-Aldrich), pH 5.0, and the
reaction was allowed to proceed for 5 h at 37uC. The reaction was
stopped by adding an equal volume of 0.1% TFA. The peptide was
adsorbed to a SepPak C18 mBondapak cartridge (Waters Corpora-
tion, Milford, MA, USA), which was then washed with 0.1% TFA
and eluted with 80% ACN in 0.1% TFA. Fractions containing
peptide were pooled (based on A280) and lyophilized.
Animals
Adult male PAM
+/2 mice were used for all reported
experiments. Male PAM
+/2 mice (back-crossed more than 15
generations into C57BL/6J mice, Jackson Laboratory, Bar
Harbor, ME, USA) were mated with WT female C57BL/6J mice
(Jackson Laboratory); weanlings were genotyped as described [6].
Dietary copper manipulations were carried out as described [5,6].
WT and PAM
+/2 mice were made copper deficient by keeping
them on a copper-deficient diet, Harlan Teklad TD80388
(Harland Laboratories, Inc., Frederick, MD, USA), with reverse
osmosis treated water for 9–10 wk. Copper-supplemented mice
were provided with Harlan Teklad control diet #2018 or normal
mouse chow and deionized reverse osmosis treated water
supplemented with 300 ppm CuSO4N5H20 (70 ppm Cu) for 14–
16 d. Control mice were provided with normal mouse chow or
Harlan Teklad control diet #2018 and deionized reverse osmosis
treated water [6]. Mice were group housed, with lights off from 7
pm to 7 am, room temperature at 20–22uC, and were weighed so
that control and test groups were of equal average weight. They
were brought to the laboratory in their home cages and allowed to
acclimate for several hours to avoid any effect of anesthetics and
circadian rhythms on the pituitary. Mice were sacrificed by
decapitation between 10 am and 2 pm.
Sample Preparation
According to genotype and diet, pituitaries were harvested,
pooled into a group containing 2–4, and homogenized into
100 mL/pituitary freshly made ice-cold acidified acetone (acet-
one:H2O:HCl=40:6:1, v/v/v) using a ground glass homogenizer
and pestle. The homogenizer was rinsed with an additional
100 mL/pituitary of the same solution. Following centrifugation at
1,0006g for 90 min, supernatants were transferred to a new glass
tube and subjected to vacuum centrifugation for 90 min to remove
the acetone; the remaining sample was frozen and lyophilized
overnight. For analysis, the lyophilized samples were dissolved into
2% ACN aqueous solution with 0.1% FA and 0.01% TFA
(20 mL/pituitary). For label-free quantitation, eight separate sets of
WT and PAM
+/2 mice kept on a normal diet were analyzed; three
separate sets of PAM
+/2 mice kept on a normal or copper-
supplemented diet were compared; and three separate sets of WT
and PAM
+/2 mice kept on a normal or copper-deficient diet were
compared, with the number of biological replicates defined for
each experiment below. Each sample in the comparison set
included the same number of pituitaries (2–4 pituitaries/sample as
mentioned above) from mice of different genotypes or diets but
raised during the same time.
For labeling-based quantitation of amidated peptides, samples
were grouped based on the isotopic chemical labels they would
receive. For these experiments, only genotype effects were
investigated as the labeling reaction was performed to compare
the peptide levels in PAM
+/2 mice with those in WT mice on a
normal diet as described previously [23]. The sample solution was
adjusted to pH 9 with 1 M phosphate buffer and 1 M NaOH.
The control (e.g., WT on a normal diet) and the experimental
(e.g., PAM
+/2 on a normal diet) samples were labeled with
succinic anhydride (SA)—5 mL of 2 M light form (SA-H) and
heavy form (SA-D)—in dimethyl sulfoxide (DMSO), respectively.
The reagents were thoroughly mixed by vortex and centrifuged,
followed by incubation for 10 min at 20–22uC. After incubation,
the addition of NaOH for adjusting the sample solutions to pH 9
and SA for labeling was repeated four times. The remaining SA
was quenched by 20 mL of 2.5 M glycine for 40 min at 20–22uC.
The labeled control and experimental samples were then
combined, followed by adjustment to pH 9. Next, 10 mLo f2M
hydroxylamine solution was added before the mixture was reacted
at 20–22uC for 30 min. Following all of the reactions, the
combined sample was desalted and pre-concentrated by using a
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solvent of the eluent from the spin column was evaporated in a
SpeedVac (Thermo Fisher Scientific, Waltham, MA, USA) and
the labeled peptides were reconstituted into 2% ACN aqueous
solution with 0.1% FA and 0.01% TFA.
LC-MS Analysis of Amidated Peptides
After labeling the samples were analyzed with an Ultraflex II
MALDI-TOF/TOF mass spectrometer (Bruker Daltonics, Bill-
erica, MA) in the mass range of 600–5000 Da. Specifically, 1 mLo f
each sample mixed with 1 mL of 10 mg/mL a-CHCA in 70%
ACN aqueous solution containing 0.1% FA and 0.01% TFA was
spotted onto a gold MALDI target. Each sample was spotted onto
three MALDI sample spots to provide technical replicates. The
spectra obtained with a total of 500 laser shots were summed. As
the neuropeptides in mouse pituitary have been well characterized,
peptides were identified by matching their parent ion masses
before labeling within 20 ppm of the theoretical masses of the
mouse pituitary peptides previously reported [29,30]. SA-based
isotopic labeling introduced a mass difference of 4 Da between the
light- and heavy-labeled samples in MALDI-TOF MS analysis.
For each peptide, quantitation was performed by calculating the
peak intensity ratio of the light over heavy forms. Eight biological
replicates were used to study the peptides in WT versus PAM
+/2
mice on a normal diet. Statistical tests with the technical and
biological replicates were performed as previously described [23].
Briefly, a two-stage mixed model commonly used in microarray
analysis was applied here. In the first stage, the general differences
between MS runs composed of labeling and treatment combina-
tions were removed. The second stage involved a mixed model
that was fitted to each peptide in terms of genotype.
LC-MS Analysis of Glycine-extended and Hydroxyglycine-
extended Peptides
Endogenous glycine-extended peptides were identified by
signature fragment ion mass matching and elution order, as well
as the widely used tandem MS (MS
2) matching approach. For LC
ESI-IT MS and MS
2, analyses were performed using a capillary
LC system (CapLC, Micromass, Manchester, UK) coupled to an
HCTultra mass spectrometer (Bruker Daltonics). Endogenous
hydroxyglycine-extended peptides were identified by parent ion
mass matching, parent ion instability, and elution order with the
CapLC coupled to the Ultraflex II MALDI-TOF/TOF mass
spectrometer described above.
Peptide standards consisting of glycine- and hydroxyglycine-
extended forms were used to assist the identification of partially
processed peptides by providing information on signature
fragment ions and elution order; here, 2 mLo f1mM ACTH(1-
13)-Gly and 2 mLo f1 0mM ACTH(1-13)-Gly-OH were added to
6 mL of pituitary extract from WT mice. The mouse pituitary
extracts or the spiked samples were separated by capillary LC with
Solvent A (95% water, 5% ACN, 0.1% FA, and 0.01% TFA), and
Solvent B (5% water, 95% ACN, 0.1% FA, and 0.01% TFA). The
45-min gradient was programed from 3% B to 20% B in 5 min, to
40% B in another 19 min, continued to 80% B in 7 min, and held
at 80% B for 3 min before ramping back to 3% B. The fractions
were immediately subjected to ESI-IT MS or MALDI-TOF/TOF
MS, followed by MS
2 analyses. The fragment ion mass matches
were considered positive when within 0.2 Da from the ESI-IT
MS
2 analysis, and the parent ion mass matches when within
5 ppm from the MALDI-TOF MS analysis.
To test the stability of hydroxyglycine-extended peptide, 0.5 mL
of 100 mM ACTH(1-13)-Gly-OH aqueous solution with 0.1% FA
and 0.01% TFA (pH,3) was deposited on a steel MALDI plate
with 0.5 mL of 10 mg/mL a-CHCA in ACN aqueous solution
(ACN/H2O=70/30, v/v). The air-dried sample spot was
analyzed by MALDI-TOF MS in the linear and reflectron modes,
sequentially. The laser power was consistent during the acquisi-
tion, and 500 laser shots were summed for each spectrum. In
addition, 50 mL of 100 mM ACTH(1-13)-Gly-OH in acidic
aqueous solution was mixed with 50 mL of ACN for ESI-IT MS
analysis with direct infusion. The mass-to-charge ratios (m/z)o f
doubly charged ACTH(1-13)-Gly-OH and its amidated form,
ACTH(1-13)-NH2, were used as parent ions to be first isolated and
then fragmented. The most intense fragment ion in this first-step
fragmentation was again isolated and then further fragmented.
The identified peptides were quantified by a label-free MS-
based approach using LC-MALDI-TOF MS [26,27]. Briefly,
5 mL samples prepared from the pituitaries of mice of different
genotypes or mice maintained on different diets were separated
using the CapLC system described above. A total of 24 1-min
fractions, collected between 20 and 45 min, were spotted for
MALDI-TOF MS analysis. The a-CHCA (1 mL of 10 mg/mL)
was added to each air-dried sample spot. The AutoeXecute
function in the Ultraflex II mass spectrometer was used to
automatically acquire MS data for each sample in the mass range
of 900–2500 Da. To obtain reproducible results for quantitative
analysis, sets of pituitary extracts prepared from mice of different
genotypes or mice kept on different dietary regimens were
subjected to parallel analyses with identical parameters from
sample handling to LC-MS analysis. The amidated peptides were
first confirmed by MALDI-TOF MS
2, and then used for internal
calibration. The peak annotations to glycine- or hydroxyglycine-
extended peptides were made by parent ion mass matches within
5 ppm and via peak elution order. Intensities of peaks annotated to
one peptide but eluted in several consecutive fractions were
summed after normalization. The relative amounts of partially
processed peptides compared to their amidated forms were
indicated by the ratio of their corresponding intensities (glycine-
extended peptide/amidated peptide or hydroxyglycine-extended
peptide/amidated peptide) within the same sample.
To minimize the effects of experimental error, the comparison
of glycine-extended peptide relative levels under different
manipulations was conducted within pairs of samples that were
prepared and analyzed at the same time. For example, a ratio for
WT to PAM
+/2 mice on a normal diet was calculated by dividing
the ratio of the glycine-extended peptide peak to the amidated
peptide peak for WT by the same ratio for PAM
+/2. Statistical
tests were then performed with this second ratio across biological
replicate pairs analyzed at different times. Because the ratio of the
glycine-extended peptide to the amidated peptide for WT was
almost zero in most cases, we divided the ratio for WT by the ratio
for PAM
+/2 in order to avoid infinite values during the statistical
tests.
As with other peptides, the abundance of partially processed
joining peptide (JP) peptide was analyzed as a ratio to the
abundance of amidated peptide to minimize experimental error
associated with different runs. In this case, the abundance ratio
was analyzed with a left-censored log-normal regression model
using SAS software (SAS Institute Inc., Cary, NC). The data was
considered left-censored because peptides were only detected
when the abundance surpassed the MS detection limit. Conse-
quently, observations where the abundance of partially processed
peptide present was less than the MS detection limit, and the
amidated peptide was measured, were treated as left-censored.
This model included the effects of partially processed peptides,
genotypes, and interactions between partially processed peptide
and genotype.
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Identification of Glycine-extended Peptides
The production of each amidated peptide must proceed
through glycine- and hydroxyglycine-extended intermediates.
Since levels of these intermediates were expected to be low, we
utilized the pituitary, a tissue rich in peptides, for our studies;
although the neuropeptides in mouse pituitary have been well
characterized, these reaction intermediates have not been detected
[28,31,32]. Characterization of these amidation intermediates is
challenging, not only because of their low levels compared to the
fully processed peptides, but also due to the restrictions imposed by
MS detection limits and dynamic range. Nonetheless, among
several observed amidation intermediates, glycine-extended join-
ing peptide (JP-Gly) was identified with good sequence coverage
via ESI-IT MS
2 (Fig. 1).
For peptides that did not produce full coverage of their fragment
ions with MS
2 analysis, identifications were based on their parent
ions, signature fragment ions, and elution order relative to the
amidated forms. We determined this for amidated, glycine-
extended, and hydroxyglycine-extended synthetic ACTH(1-13)
before using this information for endogenous peptide identifica-
tion. The signature fragment ions for glycine-extended peptides
reflect the presence of a C-terminal glycine instead of a C-terminal
amide. Therefore, the glycine-extended peptide is expected to
consist of the same set of b ions, and a set of singly charged y ions,
with a mass difference of ,58 Da (C2H5NO2 minus NH3)a s
compared to its amidated product. These predictions were well
supported by the fragment ions generated from synthetic
ACTH(1-13)-Gly versus ACTH(1-13)-NH2, and from endogenous
JP-Gly versus JP-NH2 (Fig. 1).
Based on the signature fragment ion assignments, we identified
the endogenous glycine-extended forms of oxytocin (OT-Gly) and
arginine-vasopressin (AVP-Gly) with LC-ESI-IT MS
2. As shown
in Figure 2A, identical b6, b7, and b8 ions between OT-Gly and
OT-NH2, together with the singly charged y ions and doubly
charged (M-17) ions of OT-Gly, with 58 and 29 Da mass
differences, respectively, from those of OT-NH2, suggested the
assignment of OT-Gly. The disulfide bond between cysteine 1 and
cysteine 6 hindered cleavages to form smaller b ions and larger y
ions. In addition, the identities of these glycine-extended peptides
were confirmed by their LC elution times in comparison to those
of synthetic peptides. ACTH(1-13)-NH2, ACTH(1-13)-Gly-OH,
and ACTH(1-13)-Gly showed increasingly longer retention times
on the reversed-phase column. Accordingly, we observed that JP-
Gly, AVP-Gly, and OT-Gly eluted after the corresponding
amidated peptides.
Relative Quantification of Glycine-extended versus
Amidated Peptides
There are several approaches for comparing the relative levels
of peptides, including stable isotope labeling and label-free
approaches [20,23,26,27,33]. We used a label-free LC-MALDI-
TOF MS approach here because it requires less sample processing
and is well suited to characterizing peptides present at levels near
the MS detection limit. Although neither form of oxytocin was
observed by LC-MALDI-TOF MS, this technique provided
enough sensitivity and resolution for us to quantify JP-Gly and
AVP-Gly, relative to their amidated forms. Automated MS
acquisition provided similar peptide profiles for samples from
different runs, which shows the replicate reproducibility and the
comparable amount of most peptides. As expected, in WT mice
kept on a normal diet, levels of JP-Gly and AVP-Gly were very low
when compared to levels of JP-NH2 and AVP-NH2, respectively.
For example, JP-Gly levels were 100–1000-fold below JP-NH2
levels, and AVP-Gly levels were about 1000-fold below AVP-NH2
levels. This same ratio was calculated for PAM
+/2 mice. If the
level of PAM in the corticotropes or in the hypothalamic neurons
that produce AVP is limiting, one would expect to see an increase
in the ratio of glycine-extended to amidated peptide in the
PAM
+/2 mice. The JP-Gly/JP-NH2 ratio for WT mice was
significantly smaller (p,0.05) than the same ratio for PAM
+/2
mice, and the effect of PAM haploinsufficiency on the AVP-Gly/
AVP-NH2 ratio was more dramatic, with a greater than 5-fold
drop in this ratio (p,0.0005) (Fig. 3A).
Figure 1. Analysis of mouse pituitary extracts using capillary LC coupled to ESI-IT MS
2. Mass spectra of amidated (top) and glycine-
extended (bottom) forms of (A) synthetic adrenocorticotropic hormone (ACTH) (1-13), and (B) endogenous joining peptide (JP). The assignment of b-
and y-ions matches expected fragments within 0.2 Da.
doi:10.1371/journal.pone.0028679.g001
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next asked whether the ratio of glycine-extended to amidated
peptide was altered by copper deficiency in WT or PAM
+/2 mice
(Fig. 3B). If a lack of copper limits the ability of PAM to catalyze
this reaction, one would expect the glycine-extended to amidated
peptide ratio to be increased by copper deficiency. In PAM
+/2
mice, this is what was seen for JP: JP-Gly accumulated when these
mice were copper deficient (p,0.05). For AVP-Gly, a trend
towards accumulation of the glycine-extended peptide was
observed (p,0.1) in the PAM
+/2 mice. For WT mice, a trend
towards accumulation of JP-Gly was observed with copper
deficiency (p,0.1), but there was no evidence for accumulation
of AVP-Gly in copper deficiency. Copper supplementation did not
reduce the accumulation of JP-Gly or AVP-Gly observed in
PAM
+/2 mice, although there is a large variation for AVP-Gly
(Fig. 3C). Overall, both lower levels of PAM and a copper-
deficient diet induced accumulation of JP-Gly, while AVP-Gly
accumulation was increased only by a reduction in PAM levels.
Amidated peptide remained the major product even when
PAM
+/2 mice were made copper deficient.
Identification of the Hydroxyglycine-extended
Intermediates
Although test tube studies and metabolic labeling revealed the
two-step nature of the amidation reaction [28], hydroxyglycine-
extended peptides have not been identified in tissue. Their
presumed low abundance compared to their amidated forms
makes measurement of hydroxyglycine-extended peptides chal-
lenging. In addition, it is known that hydroxyglycine-extended
peptides are unstable in basic aqueous solutions, generating
amidated peptide non-enzymatically [34]. Our data indicate that
hydroxyglycine-extended intermediates are not stable in the gas
Figure 2. Analysis of mouse pituitary extracts using capillary LC coupled to ESI-IT MS
2. Mass spectra of amidated (top) and glycine-
extended (bottom) forms of (A) oxytocin and (B) arginine-vasopressin. The labeled b- and y-ions are the signature fragment ions used for their
identification.
doi:10.1371/journal.pone.0028679.g002
Figure 3. Effects of PAM haploinsufficiency and dietary copper (Cu) on the amidation of joining peptide (JP) and arginine-
vasopressin (AVP). Pituitary samples were taken from WT and PAM
+/2 mice maintained on normal, copper-deficient or copper-supplemented
diets. In order to take into account differences in the sample preparation and mass spectrometry, for each peptide in each sample, the ratio of
glycine-extended to amidated peptide was calculated, with higher numbers indicating an accumulation of glycine-extended peptide. The effects of
(A) haploinsufficiency, (B) copper deficiency and (C) copper supplementation were then assessed by comparing the ratios between the pairs of
samples to indicate the extent of the glycine-extended peptide accumulation. For example, (A) reports the WT normal diet value divided by the
PAM
+/2 normal diet value. N is the number of biological replicate pairs. Error bar, SEM. Student’s t-test: ***, p,0.0005; **, p,0.05; *, p,0.1.
doi:10.1371/journal.pone.0028679.g003
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peptide. During MALDI-TOF MS analysis, ACTH(1-13)-Gly-
OH produced from ACTH(1-13)-Gly using purified PHM was
largely converted into ACTH(1-13)-NH2 (Fig. 4A).
We confirmed that ACTH(1-13)-Gly-OH decomposed during
MS measurement by using the reflectron mode in our MALDI-
TOF MS analysis. Just as with the c-carboxyglutamate residue in a
peptide [35], the ion lasts long enough to enter the field-free region
and then fragments. In the linear mode, the peptide fragments
reach the detector as a single peak with the hydroxyglycine-
extended peptides. However, during reflectron operation, the
decomposition products are separated well from the hydroxygly-
cine-extended peptides and dominate the MS detection. There-
fore, we observed a greatly reduced relative intensity of ACTH(1-
13)-Gly-OH compared to ACTH(1-13)-NH2 in the reflectron
mode compared to the linear mode, which indicates that
ACTH(1-13)-Gly-OH is converted into ACTH(1-13)-NH2 during
MS analysis (Fig. 4A).
We further investigated the nature of this instability by using
ESI-IT MS
2, where we isolated the parent ions of either ACTH(1-
13)-NH2 or ACTH(1-13)-Gly-OH, and then carried out corre-
sponding MS
2 and/or MS
3 analysis. After conducting MS
2 on the
isolated ACTH(1-13)-Gly-OH parent ion, we observed a single
peak corresponding to ACTH(1-13)-NH2. This peak produced the
same fragment ions as the ones produced from MS
2 of isolated
ACTH(1-13)-NH2 (Fig. 4B). Both MALDI-TOF and ESI-IT
observations support the idea that hydroxyglycine-extended
peptides are detected with the corresponding amidated form in
the same MS scan because of their decomposition. Using a similar
criterion (a peak that decomposes into the amidated form), the
expected elution order, and a parent ion mass match within 5 ppm
by MALDI-TOF MS, we confirmed the identity of hydroxygly-
cine-extended JP (JP-Gly-OH) from mouse pituitary.
Quantification of Hydroxyglycine-extended Precursors
versus Amidated Peptides
In WT mice on a normal diet, JP-Gly-OH levels were generally
at or below the MS detection limit, and were approximately 2000-
fold (or more) below the levels of JP-NH2 (Fig. 5). When peptide
levels were below the MS detection limit, an average ratio of
hydroxyglycine-extended peptide to amidated peptide at the
detection limit was used to allow all LC-MS runs to be included.
In PAM
+/2 mice, the levels of JP-Gly-OH were often above the
detection limit and the ratio of JP-Gly-OH to JP-NH2 was 7.5-fold
higher than the same ratio observed in WT mice (p,0.1) (Fig. 5A),
suggesting that the amount of PAL had become limiting. In
addition, levels of JP-Gly-OH were ,70-fold lower than levels of
JP-Gly (p,0.001), indicating that the monooxygenase reaction is a
slower step in peptide amidation.
Figure 4. Conversion of ACTH(1-13)-Gly-OH to its amidated form ACTH(1-13)-NH2 during the measurement process when analyzed
by MALDI-TOF MS and ESI-IT MS
2. (A) The table shows the assessment of the amidated and hydroxyglycine-extended ACTH(1-13) peaks in
MALDI-TOF MS. (B) With manual ESI-IT MS
2, ACTH(1-13)-NH2 and ACTH(1-13)-Gly-OH were respectively isolated, and then fragmented. The MS
2 of
ACTH(1-13)-NH2 matches the MS
3 of ACTH(1-13)-Gly-OH.
doi:10.1371/journal.pone.0028679.g004
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under Different Manipulations
A total of 12 amidated peptides with or without other post-
translational modifications, such as N-terminal acetylation, were
identified in adult male mouse pituitary extracts with MS
2
(Table 1). MALDI-TOF MS was then used to quantify the
identified amidated peptides as a function of genotype. Compared
to ESI, MALDI-TOF MS simplified the peptide profiles with only
singly charged peptides [25,36,37,38]. In this study, a-CHCA was
used as matrix to provide homogenous distribution of peptides on
the sample spots. The instrument parameters stayed the same
throughout the analyses on all of the sample spots to ensure
reproducible results. Only spectra with similar peptide profiles
over a threshold of 1000 counts were summed to reflect the
peptide relative levels. Although many reagents are available
[23,36,39], SA was used for labeling quantitation in this study
because it is stable and commercially available. Since the mass
difference between the light and heavy forms of SA is about 4 Da,
the singly labeled peptides in the control and experimental samples
appear as a pair of peaks separated by 4 Da in the mass spectra
(data not shown). Most of the observed peptides did not show
significant changes between PAM
+/2 and WT mice, except for
three: alpha-melanocyte stimulating hormone (a-MSH), JP, and
diAc-a-MSH, which were 1.42-, 1.56-, and 1.74-fold higher
(p,0.05) in PAM
+/2 mice compared to WT mice, respectively.
Discussion
Detecting Amidation Reaction Intermediates
We identified JP-Gly, derived from pro-opiomelanocortin
(POMC), AVP-Gly, from pro-vasopressin-neurophysin, and OT-
Gly, from pro-oxytocin-neurophysin. Other POMC-derived
peptides such as a-MSH were observed only in their mature
forms with C-terminal amidation, mono- or di-N-terminal
acetylation, and/or methionine oxidation. JP, an acidic peptide
located between c-MSH and ACTH in POMC, is a normal end-
product of POMC processing and has been used as an indicator of
corticotrope function, POMC processing, and amidation [40,41].
AVP and OT, which regulate plasma osmolaltiy and maternal
behavior, respectively, are synthesized in the hypothalamus,
transported to the neural lobe of the pituitary, and stored there
until released [42,43].
Several factors may have contributed to our inability to detect
additional glycine-extended peptides. First, their intrinsic low
levels, especially when compared to the levels of their amidated
counterparts, render most glycine-extended peptide ions below the
MS detection limit. Second, the a-MSH series of peptides, which
end in -Val-NH2, are better substrates for PAM than JP (-Glu-
NH2), OT (-Gly-NH2), and AVP (-GlyNH2), facilitating more
complete a-amidation [44]. Third, many of the undetected
partially processed peptides have multiple other post-translational
modifications [45]; perhaps the temporal formation of the various
modifications determines whether specific partially processed
peptides can be detected.
MS-based Label-free Quantitation
It is worth noting that most quantitative studies focus on the
same peptides in multiple samples following different manipula-
tions. Here, on the other hand, we investigated how the relative
levels of two related but distinct peptides changed with genetic and
dietary manipulations using a label-free LC-MALDI-TOF MS
Figure 5. Expected abundance of JP-Gly-OH relative to JP-NH2
in the pituitaries of WT and PAM
+/2mice on a normal diet. Ni s
the number of biological replicates. Error bar, SEM. *, p,0.1.
doi:10.1371/journal.pone.0028679.g005
Table 1. Amidated peptides identified in adult male mouse pituitary extracts.
Precursor Peptide name Sequence MH
+
theor.
Prooxytocin Oxytocin CYIQNCPLG-amide 1007.44
Provasopressin Vasopressin CYFQNCPRG-amide 1084.45
Proopiomelanocortin DesAc-a-MSH SYSMEHFRWGKPV-amide 1622.79
Proopiomelanocortin Dehydro-a-MSH Ac-dehydroS-YSMEHFRWGKPV-amide 1646.79
Proopiomelanocortin a-MSH Ac-SYSMEHFRWGKPV-amide 1664.80
Proopiomelanocortin a-MSH, Met-oxidized Ac-SYS-Mox-EHFRWGKPV-amide 1680.80
Proopiomelanocortin DiAc-a-MSH DiAc-SYSMEHFRWGKPV-amide 1706.81
Proopiomelanocortin DiAc-a-MSH, Met-oxidized DiAc-SYS-Mox-EHFRWGKPV-amide 1722.81
Proopiomelanocortin JP AEEEAVWGDGSPEPSPRE-amide 1940.86
Proopiomelanocortin Ac-JP Ac-AEEEAVWGDGSPEPSPRE-amide 1982.87
Proopiomelanocortin Arg-JP RAEEEAVWGDGSPEPSPRE-amide 2096.96
Proopiomelanocortin Glycosylated JP AEEEAVWGDGSPEP-HexHexNAcS-PRE-amide 2305.99
All masses listed here are monoisotopic. Abbreviations: MSH, melanocyte stimulating hormone; JP, joining peptide.
doi:10.1371/journal.pone.0028679.t001
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acid compositions, they may have different ionization efficiencies;
therefore, the ratio of partially processed peptides to amidated
peptides may not reflect the exact relative amount of the two
peptides. However, the ionization efficiency differences for these
peptides are eliminated when we compare the ratios of the two
related peptides from samples following different manipulations.
Therefore, the ratio difference reflects relative peptide level
changes in response to various manipulations. This approach
should provide a robust comparison of peptides present at very low
levels.
Characterization and Quantification of Hydroxyglycine-
extended Peptides
Production of amidated peptides from their glycine-extended
precursors involves formation of hydroxyglycine-extended inter-
mediates. This reaction intermediate has been identified in test
tube assays and by metabolic labeling [28], but not in tissue,
perhaps reflecting its low abundance and intrinsic instability. As
early as 1991, Bundgaard et al. [46] reported non-enzymatic,
base-catalyzed hydrolysis of hydroxyglycine-extended peptides and
their derivatives. Acid- or base-catalyzed deprotonation of the
hydroxyl moiety of carbinolamides has also been proposed
[47,48]. Here, we showed that the conversion of hydroxyglycine-
extended peptides to their amidated forms also occurs in the gas
phase during MS. We employed this conversion as a criterion to
aid in our assignment of hydroxyglycine-extended peptides.
Although more investigation is needed to reveal the decomposition
mechanism, we hypothesize that the acid-catalyzed decomposition
of hydroxyglycine-extended peptides is accelerated by an initial
decarboxylation step [35,48].
The ability to detect both JP-Gly and JP-Gly-OH in tissue
extracts makes it possible to determine the rate-limiting step in
producing JP-NH2 by this two-step reaction. Kinetic studies with
purified PHM and PAL revealed a higher affinity of PHM for its
peptide substrate and a higher turnover number for PAL [49].
The fact that levels of JP-Gly-OH were approximately 74-fold
lower than levels of JP-Gly for the same amount of JP-NH2
supports the hypothesis that PHM is the rate-limiting enzyme.
Assays of purified PAM are consistent with this conclusion; kcat
values for PAL are approximately 5-fold higher than kcat values for
PHM [49]. Genes encoding bifunctional PAM appear to have
evolved from separate genes encoding PHM and PAL [50]. The
remarkable sensitivity of hydroxyglycine-extended peptides to
their acidic/basic environment may be important in species whose
genomes encode monofunctional PHM. Examples include Dro-
sophila [4], Planaria [51], Calliactis [52], and the human parasite
Schistosoma mansoni [53], where a monofunctional PHM gene is not
always co-expressed with PAL. Compared to WT mice, PAM
+/2
mice accumulated JP-Gly-OH over amidated JP, suggesting that
levels of PAL can become limiting. If the peptidylglycine product
of the PHM reaction were passed directly to PAL, one would not
expect to see a shift in this ratio. Future work on the stability of
hydroxyglycine-extended peptides will provide greater insights into
PAL catalytic mechanisms and a-amidation catalyzed by PHM in
the absence of PAL.
PAM Haploinsufficiency and Manipulation of Dietary
Copper Produce Small Changes in Glycine-extended
Peptides
PAM
+/2 mice exhibit increased anxiety-like behavior and a
decreased ability to regulate body temperature in a cold room
[5,6]. These deficits could reflect abnormal levels of many different
amidated peptides or diminished levels of PAM protein in the
central nervous system. A c-secretase-mediated cleavage in the
transmembrane domain of PAM releases a soluble cytosolic
fragment that accumulates in the nucleus and alters gene
expression [7,8]. Using our ability to quantify peptidylglycine
intermediates in the pituitary as a way to predict corresponding
changes in the brain, these possibilities can be distinguished.
The LC-MS-based approach used here allowed us to screen
peptide content with high throughput and sensitivity. When
detectable, we found glycine-extended peptides present at levels
100–1000-fold below those of their amidated products in WT
mice. Based on radioimmunoassay data, the TRH-Gly/TRH-
NH2 ratio in the central nervous system is much higher, perhaps
reflecting the diminished affinity of PHM for substrates terminat-
ing with a Pro-Gly sequence [5,12,13]. Previous radioimmunoas-
say-based studies of secretin and gastrin, major gastrointestinal
peptides, identified high levels of secretin-Gly [54] and gastrin-Gly
[14,15]. In our study, JP-Gly and AVP-Gly were significantly
more prevalent in PAM
+/2 mice than in WT mice, but the
glycine-extended peptides were still very minor components.
In addition, in animals on a copper-deficient diet, we observed
an accumulation of JP-Gly in WT mice and enhanced accumu-
lation of JP-Gly in PAM
+/2 mice. Interestingly, copper deficiency
led to an accumulation of AVP-Gly in PAM
+/2 but not WT mice.
It is clear that changes in both PAM and copper levels interact and
affect different peptides in distinct ways. Our previous study [5],
which utilized immunoassays to distinguish TRH-NH2 from
TRH-Gly in hypothalamic extracts, demonstrated increased levels
of TRH-Gly in copper-deficient WT mice, with no effect of copper
supplementation on TRH-Gly levels in PAM
+/2 mice. Similar
responses were observed for pituitary JP-Gly and AVP-Gly in this
study. The effects of dietary limitations in copper on the amidation
reaction vary substantially for different neuropeptides, perhaps
reflecting the properties of the prohormone itself or copper
metabolism in that particular cell type.
Although PAM haploinsufficiency and manipulation of dietary
copper have the predicted effects on JP-Gly and AVP-Gly levels,
the amidated versions of these neuropeptides remain much more
prevalent. It is difficult to see how changes in the levels of
amidated versus glycine-extended peptide could account for the
phenotypic changes observed in PAM
+/2 mice or the ability of
dietary copper supplementation to ameliorate these deficits. If our
data for pituitary peptides can be applied to the brain, they
strongly suggest that the ability of PAM to affect gene expression
and copper metabolism plays a key role in determining the
phenotype of PAM
+/2 and copper deficient mice [5,7].
PAM Haploinsufficiency Produces Small Changes in
Amidated Peptides
Elimination of the PAM gene prevents the formation of
amidated peptides and is lethal in both Drosophila [4] and mouse
[1]. PAM
+/2 mice, with lower PAM activity than WT mice,
survive to adulthood and reproduce [3], but exhibit a variety of
deficits [5,6]. Consistent with these behavior deficits, our results
showed that several amidated peptides, including diAc-a-MSH, a-
MSH, and JP, undergo significant level changes (p,0.05) due to
PAM haploinsufficiency. Interestingly, pituitary levels of these
peptides appeared to be higher in PAM
+/2 mice than in WT mice.
Since pituitary levels of these peptides reflect their synthesis and
their secretion, further studies are needed to determine the
underlying cause.
PAM causes gene expression changes by relaying information
from secretory granules to the nucleus [7]. The transcripts
encoding aquaporin 1 (Aqp1) and secretory leukocyte peptidase
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+/2
compared to WT mouse pituitary [7]. Aqp1 plays an essential role
in secretory granule biogenesis [55,56]. PAM
+/2 mice may have
an impaired regulated secretory pathway. Reducing levels of Slpi,
which inhibits elastase, cathepsin G, trypsin, and chymotrypsin,
may contribute to an increase in POMC processing. Pituitary cells
overexpressing PAM showed a decrease in POMC processing
[57]. In addition, our results provide direct evidence that a-MSH
and JP increase in PAM
+/2 mice. This was demonstrated, albeit
indirectly, in two prior studies [5,7].
Most of the peptides studied did not show significant changes in
the PAM
+/2 mice. Besides diAc-a-MSH, a-MSH, and JP, we also
observed other peptides derived from POMC with or without C-
terminal amidation. There was a large variation in the relative
levels of these peptides among the biological replicates. These
peptides are present in a variety of related forms in mouse
pituitary. For example, multiple corticotropin-like intermediate
lobe peptides (CLIPs) and phosphorylated CLIP have been
detected in mouse pituitary [58]. Additional studies on peptide
processing and secretion in PAM
+/2 mice are needed to better
correlate peptide processing and peptide levels with PAM activity,
and to uncover other roles for PAM in mouse behavior.
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